ACST has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ACST has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Acasti Pharma's enterprise value is $4.80 Mil. Acasti Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00 Mil. Therefore, Acasti Pharma's EV-to-Revenue for today is .
The historical rank and industry rank for Acasti Pharma's EV-to-Revenue or its related term are showing as below:
During the past 13 years, the highest EV-to-Revenue of Acasti Pharma was 13217.87. The lowest was -2693.55. And the median was -186.18.
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
As of today (2024-04-18), Acasti Pharma's stock price is $3.06. Acasti Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.00. Therefore, Acasti Pharma's PS Ratio for today is .
The historical data trend for Acasti Pharma's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Acasti Pharma's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Acasti Pharma's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Acasti Pharma's EV-to-Revenue falls into.
EV-to-Revenue is a similar ratio to PS Ratio, except here Enterprise Value instead of Market Cap is used in the calculation.
Acasti Pharma's EV-to-Revenue for today is calculated as:
EV-to-Revenue | = | Enterprise Value (Today) | / | Revenue (TTM) |
= | 4.799 | / | 0 | |
= |
Acasti Pharma's current Enterprise Value is $4.80 Mil.
Acasti Pharma's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Acasti Pharma (NAS:ACST) EV-to-Revenue Explanation
The reason Enterprise Value is used is because Enterprise Value is more real in reflecting how much an investor pays when buying a company. For detais, go to Enterprise Value.
Acasti Pharma's PS Ratiofor today is calculated as:
PS Ratio | = | Share Price (Today) | / | Revenue per Share (TTM) |
= | 3.06 | / | 0 | |
= |
Acasti Pharma's share price for today is $3.06.
Acasti Pharma's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Acasti Pharma's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
George Kottayil | director | 49 OLD BEAR BROOK ROAD, PRINCETON NJ 08540 |
A Brian Davis | director | C/O VERRICA PHARMACEUTICALS INC., 10 NORTH HIGH STREET, SUITE 200, WEST CHESTER PA 19380 |
Edward Neugeboren | director | 282 NEW NORWALK ROAD, NEW CANAAN CT 06840 |
Vimal Kavuru | director | 11 MAACKA DRIVE, HOLMDEL NJ 07733 |
Donald Olds | director | 545 PROMENADE DU CENTROPOLIS, SUITE 100, LAVAL A8 H7T 0A3 |
Amresh Kumar | officer: VP Program Management | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
Carrie D'andrea | officer: VP Clinical Operations | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
Prashant Kohli | officer: Chief Executive Officer | 206 CAMBRIDGE LANE, NEWTOWN PA 13940 |
R. Loch Macdonald | officer: Chief Medical Officer | 200 CONNELL DRIVE, SUITE 1600, BERKELEY HEIGHTS NJ 07922 |
Michael Derby | director | 303 SOUTH BROADWAY, SUITE 125, TARRYTOWN NY 10591 |
William A Haseltine | director | |
Rajitha Grace 2018 Irrevocable Trust | 10 percent owner | 40 BEY LEA ROAD, SUITE C 202, TOMS RIVER NJ 08753 |
Swami Sambamurty Iyer | 10 percent owner | 20 TULSA COURT, MONMOUTH JUNCTION NJ 08852 |
Brian D. Ford | officer: CHIEF FINANCIAL OFFICER | 3009, BOUL. DE LA CONCORDE EAST, SUITE 102, LAVAL A8 H7E 2B5 |
John Canan | director | C/O REV GROUP, INC., 111 EAST KILBOURN AVENUE, SUITE 2600, MILWAUKEE WI 53202 |
From GuruFocus
By PRNewswire • 07-05-2023
By PRNewswire PRNewswire • 12-28-2022
By PRNewswire PRNewswire • 02-07-2023
By PRNewswire PRNewswire • 12-22-2022
By PRNewswire • 07-10-2023
By PRNewswire • 06-22-2023
By PRNewswire PRNewswire • 03-30-2023
By PRNewswire PRNewswire • 05-17-2023
By Marketwired • 08-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.